Banking Recap

Bioventus Inc. to Acquire MISONIX INC for $518.0M

Misonix, Inc., a Nasdaq-listed provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products, entered into a definitive merger agreement to be acquired by Bioventus, Inc. in a cash-and-stock transaction valued at $518 million, as announced in Misonix's fiscal fourth-quarter 2021 earnings release.

Jul 29, 2021·SEC EDGAR (8-K)·pending regulatory·cash-and-stock merger

Deal value

The deal is sourced directly from Misonix's own 8-K exhibit, filed July 29, 2021, which combined preliminary quarterly revenue results with the merger announcement. The headline framing reads: "Company Enters into a Definitive Merger Agreement to be Acquired by Bioventus for $518 Million in a Cash-and-Stock Transaction."

Perella Weinberg Partners LP served as lead financial advisor to Bioventus, the acquirer, with Morgan Stanley also advising Bioventus in a non-lead capacity, per the release: "Perella Weinberg Partners LP acted as lead financial advisor to Bioventus. Morgan Stanley acted as financial advisor to Bioventus." On the target side, J.P. Morgan Securities LLC served as Misonix's exclusive financial advisor.

Jones Day served as legal advisor to Misonix, while Latham & Watkins LLP provided legal counsel to Bioventus.

The $518 million aggregate transaction value is explicitly stated in the press release headline. The excerpt reviewed did not break out the cash-versus-stock split of consideration, the per-share terms, or an expected closing date; those details were not present in the portion of the filing captured.

Not disclosed in the reviewed source: the precise cash/stock consideration mix, per-share pricing, expected closing timeline, and any termination-fee or financing details. These would require review of the full merger agreement or a subsequent proxy statement for completeness.